Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
Aim of the reviewTo assess the risk of hypovolemia for sodium–glucose cotransporter-2 (SGLT2) inhibitors treatment.MethodA systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 Octo...
Main Authors: | Xi Rong, Yawen Zhu, Bo Wen, Kai Liu, Xinran Li, Qiling Gou, Xiaoping Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.973129/full |
Similar Items
-
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01) -
Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review
by: Hammad Rahman, et al.
Published: (2023-08-01) -
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
by: Resham Raj Poudel
Published: (2013-01-01) -
Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01) -
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)